Luoxin Pharmaceuticals Group Stock Co., Ltd. (SHE:002793)
China · Delayed Price · Currency is CNY 4.820
+0.100 (2.12%)
Feb 4, 2026, 2:45 PM CST
SHE:002793 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | Dec '20 Dec 31, 2020 |
Operating Revenue | 2,457 | 2,615 | 2,329 | 3,470 | 6,370 | 6,011 |
Other Revenue | 32.7 | 32.7 | 35.27 | 117.61 | 108.29 | 85.15 |
| 2,490 | 2,647 | 2,364 | 3,588 | 6,478 | 6,096 | |
Revenue Growth (YoY) | 2.96% | 11.99% | -34.11% | -44.62% | 6.26% | -19.67% |
Cost of Revenue | 1,362 | 1,607 | 1,340 | 2,694 | 3,232 | 2,848 |
Gross Profit | 1,127 | 1,040 | 1,024 | 893.98 | 3,246 | 3,248 |
Selling, General & Admin | 1,209 | 1,418 | 1,338 | 2,229 | 2,234 | 2,341 |
Research & Development | 101.5 | 87.41 | 112.27 | 204.73 | 320.95 | 361.27 |
Other Operating Expenses | 6.16 | -2.01 | -1.2 | 40.17 | 74.48 | 67.09 |
Operating Expenses | 1,282 | 1,517 | 1,504 | 2,494 | 2,726 | 2,832 |
Operating Income | -154.5 | -476.89 | -479.63 | -1,600 | 519.59 | 416.42 |
Interest Expense | -60.56 | -64.38 | -75.97 | -122.67 | -105.18 | -50.37 |
Interest & Investment Income | 4.81 | 6.3 | 24.84 | 176.24 | 9.87 | 12.78 |
Currency Exchange Gain (Loss) | 2.09 | 2.09 | 4.19 | -8.88 | 0.64 | -0.53 |
Other Non Operating Income (Expenses) | -18.76 | -1.31 | -0.87 | -2.06 | 5.2 | 0.14 |
EBT Excluding Unusual Items | -226.93 | -534.19 | -527.45 | -1,557 | 430.11 | 378.44 |
Gain (Loss) on Sale of Investments | -208.64 | -216.58 | -4.05 | 2.01 | -3.26 | - |
Gain (Loss) on Sale of Assets | 4.93 | 0.24 | -12.18 | 1.74 | -3.31 | -5.42 |
Asset Writedown | -207.22 | -229.97 | -56.64 | -7.85 | -0.72 | -7.1 |
Legal Settlements | - | - | - | - | - | -2.17 |
Other Unusual Items | 27.65 | 27.65 | -3.8 | 98.25 | 62.38 | 43.54 |
Pretax Income | -610.2 | -952.85 | -604.11 | -1,463 | 485.2 | 407.3 |
Income Tax Expense | 90.9 | 99.4 | 164.81 | -205.64 | 63.55 | 66.33 |
Earnings From Continuing Operations | -701.1 | -1,052 | -768.92 | -1,257 | 421.65 | 340.97 |
Minority Interest in Earnings | 23.9 | 86.76 | 107.78 | 32.37 | -15.55 | -20.27 |
Net Income | -677.2 | -965.5 | -661.14 | -1,225 | 406.1 | 320.7 |
Net Income to Common | -677.2 | -965.5 | -661.14 | -1,225 | 406.1 | 320.7 |
Net Income Growth | - | - | - | - | 26.63% | -49.41% |
Shares Outstanding (Basic) | 1,056 | 1,061 | 1,084 | 1,424 | 1,450 | 1,458 |
Shares Outstanding (Diluted) | 1,056 | 1,061 | 1,084 | 1,424 | 1,450 | 1,458 |
Shares Change (YoY) | -0.78% | -2.11% | -23.91% | -1.79% | -0.51% | 31.07% |
EPS (Basic) | -0.64 | -0.91 | -0.61 | -0.86 | 0.28 | 0.22 |
EPS (Diluted) | -0.64 | -0.91 | -0.61 | -0.86 | 0.28 | 0.22 |
EPS Growth | - | - | - | - | 27.27% | -61.40% |
Free Cash Flow | 240.65 | -273.2 | 224.5 | -1,134 | -188.4 | -393.64 |
Free Cash Flow Per Share | 0.23 | -0.26 | 0.21 | -0.80 | -0.13 | -0.27 |
Dividend Per Share | - | - | - | - | 0.030 | 0.050 |
Dividend Growth | - | - | - | - | -40.00% | - |
Gross Margin | 45.28% | 39.30% | 43.33% | 24.92% | 50.10% | 53.28% |
Operating Margin | -6.21% | -18.01% | -20.29% | -44.59% | 8.02% | 6.83% |
Profit Margin | -27.20% | -36.47% | -27.97% | -34.14% | 6.27% | 5.26% |
Free Cash Flow Margin | 9.66% | -10.32% | 9.50% | -31.61% | -2.91% | -6.46% |
EBITDA | 36.86 | -285.6 | -288.45 | -1,394 | 705.83 | 587.12 |
EBITDA Margin | 1.48% | -10.79% | -12.20% | -38.87% | 10.90% | 9.63% |
D&A For EBITDA | 191.37 | 191.29 | 191.18 | 205.33 | 186.24 | 170.69 |
EBIT | -154.5 | -476.89 | -479.63 | -1,600 | 519.59 | 416.42 |
EBIT Margin | -6.21% | -18.01% | -20.29% | -44.59% | 8.02% | 6.83% |
Effective Tax Rate | - | - | - | - | 13.10% | 16.29% |
Revenue as Reported | 2,490 | 2,647 | 2,364 | 3,588 | 6,478 | 6,096 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.